A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Confirming the Efficacy and Safety of Genz-112638 in Patients with Gaucher Disease Type 1
- Registry ID
- EUCTR2008-005222-37
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE3
- Sponsor
- Genzyme Europe B.V.
- Start date
- 2009-06-29
- Last update
- 2026-08-16
Conditions
Summary
The primary objective of this study is to confirm the efficacy and safety of Genz 112638 after 39 weeks of treatment in patients with Gaucher disease type 1.
Locations
- , , UK
- , , Bulgarian Drug Agency
- , , Netherlands
View on source registry